RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ: RAPP · HEALTHCARE · BIOTECHNOLOGY
$33.00
-2.19% today
Updated 2026-04-29
Market cap
$1.58B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.86
Dividend yield
—
52W range
$8 – $42
Volume
0.3M
Rapport Therapeutics, Inc. Common Stock (RAPP) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+1.9%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-26.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.2%
Last 3 reports
Positive reaction rate
0%
0 of 3 quarters
Largest single-day move
-4.1%
2026-03-17
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-17 | $-0.72 | -6.8% | $27.62 | $26.48 | -4.1% |
| 2025-11-06 | $-0.71 | +3.0% | $26.17 | $25.66 | -1.9% |
| 2025-08-07 | $-0.75 | +2.6% | $14.61 | $14.55 | -0.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.67 | $-0.72 | -6.8% | — | — |
| 2025-09-30 | $-0.73 | $-0.71 | +3.0% | — | — |
| 2025-06-30 | $-0.77 | $-0.75 | +2.6% | — | — |
| 2025-03-31 | $-0.75 | $-0.68 | +8.7% | — | — |
| 2024-12-31 | $-0.70 | $-0.57 | +18.6% | $720000.00 | — |
| 2024-09-30 | $-0.52 | $-0.50 | +3.8% | — | — |
| 2024-06-30 | $-0.68 | $-1.70 | -150.0% | — | — |
| 2024-03-31 | $0.00 | $-1.12 | — | — | — |
Frequently asked questions
Has Rapport Therapeutics, Inc. Common Stock beaten earnings estimates?
Rapport Therapeutics, Inc. Common Stock has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +1.9% over the last 4 quarters.
How does RAPP stock react to earnings?
RAPP stock has moved an average of -2.2% in the trading day following earnings over its last 3 reports, with positive reactions in 0% of those quarters.